Article

Compact SD-OCT granted FDA clearance

A proprietary spectral-domain optical coherence tomography (SD-OCT) device (iVue, Optovue) has received FDA 510(k) clearance.

Fremont, CA

-A proprietary spectral-domain optical coherence tomography (SD-OCT) device (iVue, Optovue) has received FDA 510(k) clearance.

The device was launched outside the United States in January and is a compact version of the company's other SD-OCT device (RTVue), which was introduced in the United States in 2006.

"This regulatory clearance for the U.S. market allows us to offer the benefits of advanced OCT imaging to more segments within eye care where the economic feasibility of the larger systems simply did not work," said Paul Kealey, vice president of marketing for Optovue.

The new device's system is delivered on a standard slit lamp-style base and is composed of a 4.5-lb scanning head, a control module, laptop computer, and foot switch. The system can be mounted to a small table, and additional options for mounting in other eye-care environments may be available soon.

The compact device offers the same scanning speed and resolution as the larger system and includes scanning and reports for retina, retina nerve fiber, and cornea assessment by the clinician.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.